484 related articles for article (PubMed ID: 33867046)
1. Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial.
Hu K; Guan WJ; Bi Y; Zhang W; Li L; Zhang B; Liu Q; Song Y; Li X; Duan Z; Zheng Q; Yang Z; Liang J; Han M; Ruan L; Wu C; Zhang Y; Jia ZH; Zhong NS
Phytomedicine; 2021 May; 85():153242. PubMed ID: 33867046
[TBL] [Abstract][Full Text] [Related]
2. Effects of Lianhuaqingwen Capsules in adults with mild-to-moderate coronavirus disease 2019: an international, multicenter, double-blind, randomized controlled trial.
Zheng JP; Ling Y; Jiang LS; Mootsikapun P; Lu HZ; Chayakulkeeree M; Zhang LX; Arttawejkul P; Hu FY; Truong TNL; Perez RA; Gu X; Sun HM; Jiang JJ; Liu RJ; Ding Z; Zhan YQ; Yang ZF; Guan WJ; Zhong NS
Virol J; 2023 Nov; 20(1):277. PubMed ID: 38017515
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Lianhuaqingwen Capsules for the Prevention of Coronavirus Disease 2019: A Prospective Open-Label Controlled Trial.
Gong X; Yuan B; Yuan Y; Li F
Evid Based Complement Alternat Med; 2021; 2021():7962630. PubMed ID: 34858512
[TBL] [Abstract][Full Text] [Related]
4. Insights into forsythia honeysuckle (Lianhuaqingwen) capsules: A Chinese herbal medicine repurposed for COVID-19 pandemic.
Liang C; Hui N; Liu Y; Qiao G; Li J; Tian L; Ju X; Jia M; Liu H; Cao W; Yu P; Li H; Ren X
Phytomed Plus; 2021 May; 1(2):100027. PubMed ID: 35399819
[TBL] [Abstract][Full Text] [Related]
5. Combination of Hua Shi Bai Du granule (Q-14) and standard care in the treatment of patients with coronavirus disease 2019 (COVID-19): A single-center, open-label, randomized controlled trial.
Liu J; Yang W; Liu Y; Lu C; Ruan L; Zhao C; Huo R; Shen X; Miao Q; Lv W; Li H; Shi H; Hu L; Yang Z; Zhang L; Wang B; Dong G; Xian Y; Li B; Zhou Z; Xu C; Chen Y; Bian Y; Guo J; Yang J; Wang J; Qi W; Chen S; Chen Y; Yan B; Wang W; Li J; Xie X; Xu M; Jiang J; Wang G; Cong X; Zhu H; Shi J; Leng L; Li D; Guo L; Huang L
Phytomedicine; 2021 Oct; 91():153671. PubMed ID: 34425471
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of Lianhuaqingwen for mild or moderate coronavirus disease 2019: A meta-analysis of randomized controlled trials.
Fan Z; Guo G; Che X; Yang Y; Liu Y; Li L; Chang X; Han L; Cai X; Tang H
Medicine (Baltimore); 2021 May; 100(21):e26059. PubMed ID: 34032734
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Lianhua Qingwen Capsule in Treatment of Asymptomatic COVID-19 Patients: A Randomized, Controlled Multicenter Trial.
Zhang L; Wu L; Xu X; Yuan Y; Jiang R; Yan X; Zhang X; Gao Y; Shang H; Hu J; Wang X; Mei J; Wu S; Liu Q
J Integr Complement Med; 2022 Nov; 28(11):887-894. PubMed ID: 36342811
[No Abstract] [Full Text] [Related]
8. Arbidol combined with the Chinese medicine Lianhuaqingwen capsule versus arbidol alone in the treatment of COVID-19.
Liu L; Shi F; Tu P; Chen C; Zhang M; Li X; Li C
Medicine (Baltimore); 2021 Jan; 100(4):e24475. PubMed ID: 33530261
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Traditional Chinese Medicine, Maxingshigan-Weijing in the management of COVID-19 patients with severe acute respiratory syndrome: A structured summary of a study protocol for a randomized controlled trial.
Zeng C; Yuan Z; Pan X; Zhang J; Zhu J; Zhou F; Shan Z; Yuan Y; Ye R; Cheng J
Trials; 2020 Dec; 21(1):1029. PubMed ID: 33357239
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Lianhua Qingke Tablets in the Treatment of Mild and Common-Type COVID-19: A Randomized, Controlled, Multicenter Clinical Study.
Zhang L; Wu L; Xu X; Yuan Y; Jiang R; Yan X; Zhang X; Gao Y; Shang H; Lian B; Hu J; Mei J; Wu S; Liu Q
Evid Based Complement Alternat Med; 2022; 2022():8733598. PubMed ID: 35186107
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
12. A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial.
Takayama S; Namiki T; Ito T; Arita R; Nakae H; Kobayashi S; Yoshino T; Ishigami T; Tanaka K; Kainuma M; Nochioka K; Takagi A; Mimura M; Yamaguchi T; Ishii T
Trials; 2020 Oct; 21(1):827. PubMed ID: 33008479
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of Chinese herbal medicine versus Lopinavir-Ritonavir in adult patients with coronavirus disease 2019: A non-randomized controlled trial.
Shi N; Guo L; Liu B; Bian Y; Chen R; Chen S; Chen Y; Chen Y; Cong X; Dong G; Guo J; Hu L; Jiang J; Leng L; Li B; Li D; Li H; Li J; Li L; Liu J; Lu C; Lv W; Miao Q; Qi W; Shi Z; Shi J; Shi H; Tian Y; Wang B; Wang G; Wang J; Wang W; Xian Y; Xie X; Xiong Y; Xu C; Xu M; Yan B; Yang J; Zhang L; Zhou Z; Zhu H; Huang L
Phytomedicine; 2021 Jan; 81():153367. PubMed ID: 33260064
[TBL] [Abstract][Full Text] [Related]
14. Effects of Tanreqing Capsule on the negative conversion time of nucleic acid in patients with COVID-19: A retrospective cohort study.
Zhang X; Xue Y; Chen X; Wu JM; Su ZJ; Sun M; Liu LJ; Zhang YB; Zhang YL; Xu GH; Shi MY; Song XM; Lu YF; Chen XR; Zhang W; Chen Q
J Integr Med; 2021 Jan; 19(1):36-41. PubMed ID: 33069626
[TBL] [Abstract][Full Text] [Related]
15. Natural herbal medicine Lianhuaqingwen capsule anti-influenza A (H1N1) trial: a randomized, double blind, positive controlled clinical trial.
Duan ZP; Jia ZH; Zhang J; Liu S; Chen Y; Liang LC; Zhang CQ; Zhang Z; Sun Y; Zhang SQ; Wang YY; Wu YL
Chin Med J (Engl); 2011 Sep; 124(18):2925-33. PubMed ID: 22040504
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of Bufei Huoxue capsules in the management of convalescent patients with COVID-19 infection: A multicentre, double-blind, and randomised controlled trial.
Chen Y; Liu C; Wang T; Qi J; Jia X; Zeng X; Bai J; Lu W; Deng Y; Zhong B; He W; Xing Y; Lian Z; Zhou H; Yan J; Yang X; Yu H; Zhou J; Zhou D; Qiu L; Zhong N; Wang J
J Ethnopharmacol; 2022 Feb; 284():114830. PubMed ID: 34763045
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of Anluohuaxian in the treatment of patients with severe Coronavirus disease 2019- a multicenter, open label, randomized controlled study: a structured summary of a study protocol for a randomised controlled trial.
Zhang C; Li J; Wu Z; Wang H; Que C; Zhao H; Wang G
Trials; 2020 Jun; 21(1):495. PubMed ID: 32513299
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: a structured summary of a study protocol for a multicenter, randomized controlled trial.
Hosogaya N; Miyazaki T; Fukushige Y; Takemori S; Morimoto S; Yamamoto H; Hori M; Kurokawa T; Kawasaki Y; Hanawa M; Fujii Y; Hanaoka H; Iwami S; Watashi K; Yamagoe S; Miyazaki Y; Wakita T; Izumikawa K; Yanagihara K; Mukae H; Kohno S;
Trials; 2021 Apr; 22(1):309. PubMed ID: 33910617
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of Reduqing granules in the treatment of common cold with wind-heat syndrome: a randomized, double-blind, double-dummy, positive-controlled trial.
Ma Y; Zhang Z; Wei L; He S; Deng X; Ji A; Zhou B; Jiang D; Li M; Wang Y
J Tradit Chin Med; 2017 Apr; 37(2):185-92. PubMed ID: 29960290
[TBL] [Abstract][Full Text] [Related]
20. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
